NASDAQ · ALKS
Alkermes plc
$45.37+$0.12 (+0.27%)
Alkermes plc’s quoted price sits in the upper half of its reported 52-week range, 18.5% below the high.
Loading market information…
NASDAQ · AQST · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aquestive Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Aquestive Therapeutics, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aquestive Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | -$0.24-41.18% vs estimate | $8.72M-28.7% vs estimate |
|---|
| Q4 2024 | Mar 5, 2025 | -$0.19-35.71% vs estimate | $11.87M-9.5% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | -$0.13-8.33% vs estimate | $13.54M+3.17% vs estimate |
|---|
KEEP COMPARING
$45.37+$0.12 (+0.27%)
Alkermes plc’s quoted price sits in the upper half of its reported 52-week range, 18.5% below the high.
$41.84+$0.76 (+1.85%)
Supernus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.89% below the high.
$10.75+$0.11 (+1.03%)
Xeris Biopharma Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.87% below the high.
$26.93+$0.60 (+2.28%)
Amphastar Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.77% below the high.
$24.03+$0.80 (+3.44%)
Collegium Pharmaceutical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
$10.36+$0.05 (+0.48%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.12% below the high.
$4.05+$0.05 (+1.25%)
Vanda Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.26% below the high.
$5.41+$0.29 (+5.66%)
Journey Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 43.41% below the high.
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $10.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
